Related Experiment Video
Updated: Jun 16, 2026
Characterization of the Effects of Migrastatic Inhibitors on 3D Tumor Spheroid Invasion by High-resolution Confocal Microscopy
Published on: September 16, 2019
Differential Effects of the Proteasome Inhibitor NPI-0052 against Glioma Cells
Erina Vlashi1, Malcom Mattes, Chann Lagadec
1Department of Radiation Oncology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
Abstract:
Proteasome inhibitors are emerging as a new class of cancer therapeutics, and bortezomib has shown promise in the treatment of multiple myeloma and mantle cell lymphoma. However, bortezomib has failed to have an effect in preclinical models of glioma. NPI-0052 is a new generation of proteasome inhibitors with increased potency and strong inhibition of all three catalytic activities of the 26S proteasome. In this article, we test the antitumor efficacy of NPI-0052 against glioma, as a single agent and in combination with temozolomide and radiation using five different glioma lines. The intrinsic radiation sensitivities differed for all the lines and correlated with their PTEN expression status. In vitro, NPI-0052 showed a dose-dependent toxicity, and its combination with temozolomide resulted in radiosensitization of only the cell lines with a mutated p53. The effect of NPI-0052 as a single agent on glioma xenografts in vivo was only modest in controlling tumor growth, and it failed to radiosensitize the glioma xenografts to fractionated radiation. We conclude that NPI-0052 is not a suitable drug for the treatment of malignant gliomas despite its efficacy in other cancer types.
Insights
NPI-0052, a potent proteasome inhibitor, showed limited efficacy against glioma models. This new drug did not effectively control tumor growth or enhance radiation therapy in preclinical glioma studies.
Area of Science:
- Oncology
- Cancer Therapeutics
- Neuro-oncology
Background:
- Proteasome inhibitors represent a novel cancer therapy class.
- Bortezomib is effective for multiple myeloma and mantle cell lymphoma but not glioma.
- NPI-0052 is a next-generation proteasome inhibitor with enhanced potency.
Purpose of the Study:
- To evaluate the antitumor efficacy of NPI-0052 against glioma.
- To assess NPI-0052 as a single agent and in combination with temozolomide and radiation.
- To investigate the correlation between PTEN expression and radiation sensitivity in glioma cell lines.
Main Methods:
- Tested NPI-0052 in five different glioma cell lines in vitro and in vivo.
- Assessed combination therapy with temozolomide and fractionated radiation.
- Analyzed intrinsic radiation sensitivities and PTEN expression status.
- Evaluated p53 mutation status for radiosensitization effects.
Main Results:
- NPI-0052 demonstrated dose-dependent toxicity in vitro.
- Combination with temozolomide radiosensitized only p53-mutated glioma cell lines.
- NPI-0052 showed modest tumor growth control in vivo as a single agent.
- NPI-0052 failed to radiosensitize glioma xenografts to radiation.
Conclusions:
- NPI-0052 exhibits limited efficacy in preclinical glioma models.
- The drug is not suitable for treating malignant gliomas, despite its effectiveness in other cancers.
- Glioma intrinsic radiation sensitivity is linked to PTEN expression.